Bhagiradha Chemicals & Industries Ltd
Bhagiradha Chemicals & Industries is an Agro Chemical Company in India involved in the manufacturing of insecticides, fungicides, herbicides etc. It was Promoted by late Sri S. Koteswara Rao, a former scientist of Indian Institute of Chemical Technology, Hyderabad in the year 1993.[1][2]
- Market Cap ₹ 4,076 Cr.
- Current Price ₹ 328
- High / Low ₹ 448 / 117
- Stock P/E 188
- Book Value ₹ 50.4
- Dividend Yield 0.03 %
- ROCE 9.18 %
- ROE 5.68 %
- Face Value ₹ 1.00
Pros
Cons
- Promoter holding has decreased over last quarter: -3.25%
- Promoter holding is low: 20.3%
- Company has a low return on equity of 13.3% over last 3 years.
- Dividend payout has been low at 7.31% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
246 | 318 | 436 | 502 | 408 | 401 | |
229 | 271 | 367 | 425 | 365 | 357 | |
Operating Profit | 17 | 47 | 68 | 77 | 43 | 44 |
OPM % | 7% | 15% | 16% | 15% | 11% | 11% |
4 | 2 | 1 | 1 | 3 | 8 | |
Interest | 5 | 8 | 9 | 5 | 8 | 7 |
Depreciation | 7 | 8 | 9 | 10 | 11 | 12 |
Profit before tax | 9 | 32 | 51 | 64 | 27 | 33 |
Tax % | 27% | 27% | 30% | 29% | 32% | |
7 | 23 | 36 | 45 | 18 | 22 | |
EPS in Rs | 0.63 | 2.27 | 3.48 | 4.34 | 1.75 | 1.91 |
Dividend Payout % | -0% | -0% | 7% | 9% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 9% |
TTM: | -15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -7% |
TTM: | -25% |
Stock Price CAGR | |
---|---|
10 Years: | 50% |
5 Years: | 56% |
3 Years: | 66% |
1 Year: | 117% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 13% |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 10 | 10 | 12 |
Reserves | 124 | 147 | 182 | 303 | 318 | 615 |
43 | 62 | 81 | 50 | 62 | 88 | |
50 | 55 | 71 | 83 | 186 | 119 | |
Total Liabilities | 225 | 273 | 342 | 447 | 576 | 833 |
138 | 152 | 157 | 173 | 214 | 223 | |
CWIP | 4 | 2 | 5 | 28 | 68 | 120 |
Investments | -0 | -0 | -0 | -0 | 38 | 105 |
83 | 119 | 181 | 246 | 256 | 385 | |
Total Assets | 225 | 273 | 342 | 447 | 576 | 833 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
48 | 4 | 7 | 14 | 34 | |
-39 | -21 | -17 | -60 | -121 | |
-9 | 15 | 12 | 46 | 88 | |
Net Cash Flow | 0 | -2 | 2 | 1 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 17 | 68 | 81 | 94 | 96 |
Inventory Days | 137 | 97 | 91 | 108 | 168 |
Days Payable | 59 | 89 | 73 | 69 | 98 |
Cash Conversion Cycle | 95 | 76 | 99 | 132 | 166 |
Working Capital Days | 35 | 71 | 91 | 114 | 134 |
ROCE % | 20% | 25% | 22% | 9% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14 Nov - Monitoring Agency Report for convertible warrants issued.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
13 Nov - Investor Presentation for the Quarter and Half year ended September 30, 2024.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Submission of copies of Newspaper Publication of the Un-Audited Financial Results for the quarter ended September 30, 2024
-
Statement Of Deviation (S) Or Variation(S) For The Quarter Ended September 30, 2024
12 Nov - Statement confirming no deviation in fund utilization.
-
Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024
12 Nov - Board approved un-audited financial results for Q2 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2024TranscriptNotesPPT
Product Portfolio
The company's product portfolio includes a wide range of insecticides, fungicides, herbicides, and speciality intermediaries -
a. Insecticides: Chlorpyrifos, Diafenthiuron, Fipronil, Buprofezin, etc.
b. Fungicides: Azoxystrobin
c. Herbicides: Imazethapyr, Clodinafop-propargyl, Cloquintocet-mexyl
d. Specialty-intermediaries: R-HPPA, 2,6-Dichloroaniline, etc [1]